Advances in cytomegalovirus-preventive strategies in solid organ transplantation: defending pre-emptive therapy
Language English Country Great Britain, England Media print
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
22149614
DOI
10.1586/eri.11.156
Knihovny.cz E-resources
- MeSH
- Acyclovir analogs & derivatives therapeutic use MeSH
- Antiviral Agents therapeutic use MeSH
- Cytomegalovirus Infections prevention & control MeSH
- Ganciclovir analogs & derivatives therapeutic use MeSH
- Immunosuppressive Agents therapeutic use MeSH
- Clinical Protocols MeSH
- Humans MeSH
- Opportunistic Infections prevention & control MeSH
- Randomized Controlled Trials as Topic MeSH
- Organ Transplantation MeSH
- Valacyclovir MeSH
- Valganciclovir MeSH
- Valine analogs & derivatives therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Acyclovir MeSH
- Antiviral Agents MeSH
- Ganciclovir MeSH
- Immunosuppressive Agents MeSH
- Valacyclovir MeSH
- Valganciclovir MeSH
- Valine MeSH
Prevention of cytomegalovirus (CMV) infection is an important part of clinical care provided to patients after solid organ transplantation. While the optimal preventive strategy has not been defined, most centers rely on universal prophylaxis or pre-emptive therapy. This article comments on recent studies designed to identify strategies that effectively reduce the incidence of late-onset CMV disease as the main problem associated with prophylaxis, and on recent data regarding the development of CMV-specific immunity depending on the CMV-preventive regimen used. Despite an apparent trend to prefer prophylaxis in clinical practice, this approach does not seem to be based on robust evidence.
References provided by Crossref.org
